Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis

  • STATUS
    Recruiting
  • End date
    Jul 16, 2026
  • participants needed
    30
  • sponsor
    H. Lee Moffitt Cancer Center and Research Institute
Updated on 16 August 2021
platelet count
renal function
neutrophil count

Summary

The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating Merkel Cell Carcinoma.

Details
Condition Neuroendocrine carcinoma, Merkel cell carcinoma
Treatment Cemiplimab-Rwlc
Clinical Study IdentifierNCT04975152
SponsorH. Lee Moffitt Cancer Center and Research Institute
Last Modified on16 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically proven diagnosis of Merkel cell carcinoma (MCC)
Clinical stage I-II MCC (AJCC 8th edition)
Patients must be considered candidates for wide local surgical excision and sentinel lymph node biopsy
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged at least 18 years
ECOG performance Status of 0, 1, or 2
Adequate baseline laboratory assessments within 28 days of study registration
Adequate hepatic function: i. Total bilirubin 1.5 x upper limit of normal (ULN) (NOTE: For patients with Gilbert's syndrome, total bilirubin 3 x ULN) ii. Transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) 3 x ULN iii. Alkaline phosphatase (ALP) 2.5 x ULN
Adequate renal function: Serum creatinine 1.5 x ULN or estimated creatinine clearance (CrCl) >30 mL/min according to the method of Cockcroft and Gault
Adequate bone marrow function: i. Hemoglobin 9.0 g/dL ii. Absolute neutrophil count (ANC) 1.0 x 109/L iii. Platelet count 75 x 109/L
Patients who are HIV+ with undetectable HIV viral load are eligible
For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 months after the end of cemiplimab administration
For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner

Exclusion Criteria

Concurrent malignancy other than localized CSCC and/or history of malignancy other than Merkel cell carcinoma within 3 years of date of registration on the study, except for tumors with negligible risk of metastasis or death, such as adequately treated (BCC) of the skin, carcinoma in situ of the cervix, or ductal carcinoma in situ of the breast, or low- risk early stage prostate adenocarcinoma (T1-T2aN0M0 and Gleason score 6 and prostate-specific antigen (PSA) 10 ng/mL) for which the management plan is active surveillance, or prostate adenocarcinoma with biochemical-only recurrence with documented PSA doubling time of >12 months for which the management plan is active surveillance
Patients with hematologic malignancies (eg, chronic lymphocytic leukemia [CLL])
Ongoing or recent (within 5 years of registration date) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs). Further, patients requiring chronic immune-suppressive therapy are excluded. The following are not exclusionary: vitiligo, childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism that required only hormone replacement, or psoriasis that does not require systemic treatment
Pregnancy or lactation
Has participated in a study of an investigational agent or an investigational device within 4 weeks of the enrollment date
Receipt of a live vaccine within 28 days of the registration date
Has had prior systemic anti-cancer immunotherapy for MCC. Examples of immune modulating agents include but are not limited to blockers of CTLA-4, 4-1BB (CD137), or OX-40, therapeutic vaccines, anti-PD-1/PD-L1
Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of cemiplimab/placebo
NOTE: Patients who require brief course of corticosteroids (eg, prophylaxis
for imaging assessments due to hypersensitivity to contrast agents) are not
excluded. People taking steroids for physiologic replacement (ie, adrenal
insufficiency) are NOT excluded
Has received treatment with an approved anticancer systemic therapy within 4 weeks of the registration date or has not yet recovered (ie, grade 1 or baseline) from any acute toxicities except for laboratory changes as described in the inclusion criteria
NOTE: Patients receiving bisphosphonates or denosumab are not excluded
Prior allogeneic stem cell transplantation, or autologous stem cell transplantation
Patients who have permanently discontinued anti-cancer immune modulating therapies due to drug-related toxicity
Encephalitis, meningitis, or uncontrolled seizures in the year prior to screening
Patients with myocardial infarction within 6 months prior to the registration date
Any infection requiring hospitalization and/or intravenous antibiotic therapy within 2 weeks of the registration date
Active tuberculosis
Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency
NOTES
Patients with known HIV infection who have controlled infection (undetectable viral load (HIV RNA PCR) and CD4 count above 350, either spontaneously or on a stable antiviral regimen) are permitted. For patients with controlled HIV infection, monitoring will be performed per local standards
Patients with HBV (hepatitis B surface antigen positive; HepBsAg+) who have controlled infection (serum HBV DNA PCR that is below the limit of detection AND receiving antiviral therapy for HBV) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study drug
Patients who are HCV antibody positive (HCV Ab+) who have controlled infection
(undetectable HCV RNA by PCR, either spontaneously or in response to a
successful prior course of anti-HCV therapy) are permitted
History of immune related pneumonitis within the last 5 years
History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved 6 months prior to the registration date
History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments
Known hypersensitivity or allergy to any of the excipients in the cemiplimab drug product
Patients with a history of solid organ transplant (exception: patients with prior corneal transplant are not excluded)
Any medical co-morbidity, physical examination finding, or metabolic dysfunction, or clinical laboratory abnormality that, in the opinion of the investigator, renders the patient unsuitable for participation in a clinical trial due to high safety risks and/or potential to affect interpretation of results of the study
Known psychiatric or substance abuse disorders that would interfere with participation with the requirements of the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note